VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species)
Vaccine Information
  • Vaccine Name: cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species)
  • Target Pathogen: Ebola virus
  • Target Disease: Ebola hemorrhagic fever
  • Vaccine Ontology ID: VO_0004647
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Human
  • GP from Sudan ebolavirus gene engineering:
    • Type: Recombinant protein preparation
    • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant protein preparation
    • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The bivalent cAdVaxE(GPs/z) vaccine includes the SEBOV glycoprotein (GP) and ZEBOV GP genes together in a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Vaccination of mice with the bivalent cAdVaxE(GPs/z) vaccine led to efficient induction of EBOV-specific antibody and cell-mediated immune responses to both species of EBOV (Wang et al., 2006).
  • Challenge Protocol: Mice were challenged with a lethal dose of ZEBOV (30,000 times the 50% lethal dose) (Wang et al., 2006).
  • Efficacy: the cAdVax technology demonstrated induction of a 100% protective immune response in mice, as all vaccinated C57BL/6 and BALB/c mice survived challenge with a lethal dose of ZEBOV (Wang et al., 2006).
References
Wang et al., 2006: Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Journal of virology. 2006; 80(6); 2738-2746. [PubMed: 16501083].